Lynda Borsdorf
Family · Savanna, ILNPI 1952534380
Payments from drug & device makers
Across 106 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$193
- Novo Nordisk$138
- GSK$134
- Lilly USA, LLC$128
- Astellas Pharma US Inc$126
- AstraZeneca$118
- plus $1K from 23 others
What the payments were for
- Food & beverage$1,894100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 10 | $193 |
| Novo Nordisk | 8 | $138 |
| GSK | 7 | $134 |
| Lilly USA, LLC | 8 | $128 |
| Astellas Pharma US Inc | 6 | $126 |
| AstraZeneca | 7 | $118 |
| Bayer | 6 | $109 |
| Amgen | 5 | $90 |
| Otsuka America Pharmaceutical, Inc. | 4 | $84 |
| Sanofi-aventis U.S. LLC | 4 | $78 |
| Pfizer | 4 | $75 |
| Kowa Pharmaceuticals America, Inc. | 5 | $71 |
| Boehringer Ingelheim | 4 | $69 |
| Novartis | 4 | $57 |
| Sumitomo Pharma America, Inc. | 3 | $52 |
| Corcept Therapeutics | 3 | $51 |
| Mylan Specialty L.p. | 2 | $45 |
| Exact Sciences | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Abbott | 2 | $32 |
| Johnson & Johnson | 2 | $26 |
| AbbVie | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$1,894 in reported general payments places this provider in the 80th percentile of 4,941 family providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BetaseronInterferon Beta-1b | 11 | $108,904 |
| JardianceEmpagliflozin | 46 | $51,277 |
| EliquisApixaban | 41 | $29,670 |
| XareltoRivaroxaban | 34 | $26,946 |
| FarxigaDapagliflozin Propanediol | 18 | $22,899 |
| OzempicSemaglutide | 22 | $22,576 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $20,388 |
| Spiriva RespimatTiotropium Bromide | 26 | $18,441 |
| Advair DiskusFluticasone Propion/Salmeterol | 12 | $2,378 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,089 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,876 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 71 | $1,620 |
| Novolog FlexpenInsulin Aspart | 11 | $1,470 |
| Rosuvastatin Calcium | 182 | $1,103 |
| SynthroidLevothyroxine Sodium | 11 | $990 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerBetaseron | $109 | $108,90411 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $69 | $69,71872 claims |
| PfizerEliquis | $75 | $29,67041 claims |
| Johnson & JohnsonXarelto | $26 | $26,94634 claims |
| AstraZenecaFarxiga | $118 | $22,89918 claims |
| Novo NordiskOzempic | $138 | $22,57622 claims |
| GSKTrelegy Ellipta | $134 | $20,38823 claims |
| AbbVieSynthroid | $21 | $99011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,941 family providers in Illinois.
Other family in Savanna
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Brooke KennardBloomington$208K
- Amy BrownellElk Grove Village$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.